WO2000056369A1 - Radioactive cisplatin in the treatment of cancer - Google Patents
Radioactive cisplatin in the treatment of cancer Download PDFInfo
- Publication number
- WO2000056369A1 WO2000056369A1 PCT/US2000/006546 US0006546W WO0056369A1 WO 2000056369 A1 WO2000056369 A1 WO 2000056369A1 US 0006546 W US0006546 W US 0006546W WO 0056369 A1 WO0056369 A1 WO 0056369A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cisplatin
- radioactive
- cancer
- treatment
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Hepatocellular cancer that is non-resectable has had a median survival of six months when treated.
- a variety of chemotherapeutic agents have been given intravenously, with less-than-realistic results.
- intr-arterial cisplatin at 50 mg./m 2 caused a 50 percent remission in 28 patients; and, recently, in 67 patients, a 50 percent response.
- 95 patients have had a 50 percent remission, with median survival extended one year to 46 months depending on the classification of the tumor.
- the median survival rate for the worst group of hematomas was one year greater than the six months reported from the other therapeutic regimens.
- intra-arterial cisplatin In order to discern why intra-arterial cisplatin was superior to intravenous, we created 195 m cisplatin, and studied the same patient intravenously and intra- arterially. When the drug was given intravenously, less than five percent deposited in the tumor. When the drug was given intra-arterially, 35 to 40 percent of the drug deposited in the tumor, as witnessed by scintigraphic scans. The cisplatin that binds on the hepatoma apparently stays there for a persistent period of time and interrupts DNA metabolism. The use of intravenous cisplatin has had less than a five-percent response rate, and the arterial route is 50 percent or greater.
- the benefit to the patient would be that the non-radioactive form and the radioactive form would still behave as the drug cisplatin, since it is created radioactive by neutron bombardment and not by chemistry alteration or linkage.
- Cisplatin has been used diagnostically in a variety of tumors where its direct infusion is part of the pharmacokinetics. Therapy with 195 m cisplatin would have us in hematoma, bladder and brain tumors, but has never been proposed for this use.
- a dosage range of approximately 10mCi to 75 mCi or more, depending upon the size of the tumor, may be given in accordance with this invention for all types of solid tumor cancers and not limited to hematomas.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN00804701.4A CN1343130A (en) | 2000-03-14 | 2000-03-14 | Radioactive cisplatin in treatment of cancer |
CA002366938A CA2366938A1 (en) | 2000-03-14 | 2000-03-14 | Radioactive cisplatin in the treatment of cancer |
NZ513872A NZ513872A (en) | 1999-03-19 | 2000-03-14 | Radioactive cisplatin in the treatment of cancer |
MXPA01009458A MXPA01009458A (en) | 1999-03-19 | 2000-03-14 | Radioactive cisplatin in the treatment of cancer. |
KR1020017011896A KR20010108357A (en) | 1999-03-19 | 2000-03-14 | Radioactive cisplatin in the treatment of cancer |
PL00349955A PL349955A1 (en) | 2000-03-14 | 2000-03-14 | Radioactive cisplatin in the treatment of cancer |
EP00919400A EP1176988B1 (en) | 1999-03-19 | 2000-03-14 | Radioactive cisplatin in the treatment of cancer |
AT00919400T ATE283070T1 (en) | 2000-03-14 | 2000-03-14 | RADIOACTIVE CISPLATIN FOR CANCER TREATMENT. |
DE60016194T DE60016194T2 (en) | 2000-03-14 | 2000-03-14 | RADIOACTIVE CISPLATINE FOR CANCER TREATMENT. |
AU40094/00A AU782093B2 (en) | 1999-03-19 | 2000-03-14 | Radioactive cisplatin in the treatment of cancer |
IL14514900A IL145149A0 (en) | 1999-03-19 | 2000-03-14 | Radioactive cisplatin in the treatment of cancer |
JP2000606273A JP2003512296A (en) | 1999-03-19 | 2000-03-14 | Radioactive cisplatin in the treatment of cancer |
NO20014228A NO20014228D0 (en) | 1999-03-19 | 2001-08-31 | Radioactive cisplatin in the treatment of cancer |
HK02106701.5A HK1045119A1 (en) | 1999-03-19 | 2002-09-13 | Radioactive cisplatin in the treatment of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/272,549 US6074626A (en) | 1998-03-20 | 1999-03-19 | Radioactive cisplatin in the treatment of cancer |
US09/272,549 | 1999-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000056369A1 true WO2000056369A1 (en) | 2000-09-28 |
Family
ID=23040266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/006546 WO2000056369A1 (en) | 1999-03-19 | 2000-03-14 | Radioactive cisplatin in the treatment of cancer |
Country Status (15)
Country | Link |
---|---|
US (1) | US6074626A (en) |
EP (1) | EP1176988B1 (en) |
JP (1) | JP2003512296A (en) |
KR (1) | KR20010108357A (en) |
AU (1) | AU782093B2 (en) |
CZ (1) | CZ20013216A3 (en) |
HK (1) | HK1045119A1 (en) |
HU (1) | HUP0200717A3 (en) |
IL (1) | IL145149A0 (en) |
MX (1) | MXPA01009458A (en) |
NO (1) | NO20014228D0 (en) |
NZ (1) | NZ513872A (en) |
TR (1) | TR200102576T2 (en) |
WO (1) | WO2000056369A1 (en) |
ZA (1) | ZA200107312B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ641100A0 (en) * | 2000-03-23 | 2000-04-15 | Australia Nuclear Science & Technology Organisation | Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents |
US20030082102A1 (en) * | 2001-06-25 | 2003-05-01 | Court Wayne S. | Radioactive platinum complexes for cancer treatment |
PL370867A1 (en) * | 2001-09-24 | 2005-05-30 | Tosk, Inc. | Reduced toxicity cisplatin formulations and methods for using the same |
US20030228253A1 (en) * | 2002-06-06 | 2003-12-11 | Aranoff Shraga D. | Radiolabelled thioplatin, compositions thereof and methods of cancer treatment |
US6751280B2 (en) * | 2002-08-12 | 2004-06-15 | Ut-Battelle, Llc | Method of preparing high specific activity platinum-195m |
US20060052690A1 (en) * | 2004-09-08 | 2006-03-09 | Sirohey Saad A | Contrast agent imaging-driven health care system and method |
US20100035853A1 (en) * | 2008-08-07 | 2010-02-11 | Hyogo College Of Medicine | Method for preventing or treating cisplatin-induced nephrotoxicity |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5484612A (en) * | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
US4451447A (en) * | 1980-03-31 | 1984-05-29 | Bristol-Myers Company | Pharmaceutical formulations |
US4536386B1 (en) * | 1981-01-26 | 1995-03-07 | Robins Co Inc A H | Method of controlling emesis caused by cisplatin in cancer chemotherapy |
IL83380A (en) * | 1987-07-30 | 1991-04-15 | Teva Pharma | Stable aqueous cisplatin solutions |
ZA885929B (en) * | 1987-08-25 | 1989-04-26 | Oxi Gene Inc | Agents for use in tumor or cancer cell killing therapy |
US5844001A (en) * | 1993-02-26 | 1998-12-01 | Research Development Foundation | Combination platinum chemotherapeutic/antiestrogen therapy for human cancers |
-
1999
- 1999-03-19 US US09/272,549 patent/US6074626A/en not_active Expired - Fee Related
-
2000
- 2000-03-14 EP EP00919400A patent/EP1176988B1/en not_active Expired - Lifetime
- 2000-03-14 KR KR1020017011896A patent/KR20010108357A/en not_active Application Discontinuation
- 2000-03-14 HU HU0200717A patent/HUP0200717A3/en unknown
- 2000-03-14 TR TR2001/02576T patent/TR200102576T2/en unknown
- 2000-03-14 JP JP2000606273A patent/JP2003512296A/en active Pending
- 2000-03-14 AU AU40094/00A patent/AU782093B2/en not_active Ceased
- 2000-03-14 WO PCT/US2000/006546 patent/WO2000056369A1/en not_active Application Discontinuation
- 2000-03-14 NZ NZ513872A patent/NZ513872A/en unknown
- 2000-03-14 IL IL14514900A patent/IL145149A0/en unknown
- 2000-03-14 CZ CZ20013216A patent/CZ20013216A3/en unknown
- 2000-03-14 MX MXPA01009458A patent/MXPA01009458A/en unknown
-
2001
- 2001-08-28 ZA ZA200107312A patent/ZA200107312B/en unknown
- 2001-08-31 NO NO20014228A patent/NO20014228D0/en not_active Application Discontinuation
-
2002
- 2002-09-13 HK HK02106701.5A patent/HK1045119A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5484612A (en) * | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
Also Published As
Publication number | Publication date |
---|---|
KR20010108357A (en) | 2001-12-07 |
TR200102576T2 (en) | 2002-06-21 |
HK1045119A1 (en) | 2002-11-15 |
CZ20013216A3 (en) | 2002-01-16 |
US6074626A (en) | 2000-06-13 |
JP2003512296A (en) | 2003-04-02 |
NZ513872A (en) | 2003-08-29 |
NO20014228L (en) | 2001-08-31 |
HUP0200717A2 (en) | 2002-07-29 |
MXPA01009458A (en) | 2004-10-14 |
EP1176988A4 (en) | 2003-04-23 |
NO20014228D0 (en) | 2001-08-31 |
ZA200107312B (en) | 2002-05-22 |
IL145149A0 (en) | 2002-06-30 |
AU4009400A (en) | 2000-10-09 |
EP1176988A1 (en) | 2002-02-06 |
EP1176988B1 (en) | 2004-11-24 |
HUP0200717A3 (en) | 2004-11-29 |
AU782093B2 (en) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001267734B2 (en) | Radiotherapy | |
LEGHA et al. | 4′-(9-acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia | |
Behr et al. | High‐dose myeloablative radioimmunotherapy of mantle cell non‐hodgkin lymphoma with the iodine‐131–labeled chimeric anti‐CD20 antibody C2B8 and autologous stem cell support.[THIS ARTICLE HAS BEEN RETRACTED] Results of a pilot study | |
Gaze et al. | Multi-modality megatherapy with [131I] metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma | |
JP2002534399A (en) | Formulation and use of radium-223 for pain relief, treatment of bone cancer and modulation of bone surface targeting calcified tissue | |
WO2000050031A9 (en) | Co-administration of lucanthone and radiation for treatment of cancer | |
Tepmongkol et al. | 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status | |
WO2000056369A1 (en) | Radioactive cisplatin in the treatment of cancer | |
Ringdén et al. | Increased mortality by septicemia, interstitial pneumonitis and pulmonary fibrosis among bone marrow transplant recipients receiving an increased mean dose rate of total irradiation | |
JP2019123731A (en) | High-purity therapeutic bone agents | |
Pouillart et al. | Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trial | |
Yoo et al. | Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol | |
JP2006523664A5 (en) | ||
CA2366938A1 (en) | Radioactive cisplatin in the treatment of cancer | |
Riva et al. | Radioimmunotherapy of gastrointestinal cancer and glioblastomas | |
Jonkhoff et al. | High-dose gallium-67 therapy in patients with relapsed acute leukaemia: a feasibility study | |
Novell et al. | Therapeutic aspects of radio-isotopes in hepatobiliary malignancy | |
Risse et al. | I-131-Lipiodol therapy in liver neoplasms | |
Lin et al. | CuTira brachytherapy: a new combination of radioactive copper isotopes and the hypoxic cytotoxin, tirapazamine, for targeted tumor therapy | |
Nagai | Clinical use of interferons in the treatment of malignant brain tumors | |
CN118159304A (en) | Combination therapy of radionuclide complexes | |
Jacquy et al. | Additional myeloablation with 52Fe before bone marrow transplantation | |
US20030228253A1 (en) | Radiolabelled thioplatin, compositions thereof and methods of cancer treatment | |
Johnson | New treatment for hepatocellular carcinoma | |
Saiful Alam | Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00804701.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001/07312 Country of ref document: ZA Ref document number: 145149 Country of ref document: IL Ref document number: 200107312 Country of ref document: ZA Ref document number: IN/PCT/2001/01003/MU Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2000 606273 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 513872 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/02576 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-3216 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200100870 Country of ref document: VN |
|
ENP | Entry into the national phase |
Ref document number: 2366938 Country of ref document: CA Ref document number: 2366938 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017011896 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/009458 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000919400 Country of ref document: EP |
|
WPC | Withdrawal of priority claims after completion of the technical preparations for international publication | ||
WWP | Wipo information: published in national office |
Ref document number: 1020017011896 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-3216 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000919400 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2001-3216 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000919400 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017011896 Country of ref document: KR |